Bristol Myers Squibb (BMY) Stock: $81 Price Target And Outperform Rating

Apr 4th, 2022 10:02 EST
  • The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received an $81 price target from BMO Capital. These are the details.

The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received an $81 price target from BMO Capital. And BMO Capital analyst Evan Seigerman increased the price target on Bristol-Myers from $74 while maintaining an “Outperform” rating on the shares.

Seigerman adjusted the rating as the company’s new safety and efficacy data for mavacamten from the VALOR-HCM trial at ACC improves the setup for sentiment regarding its PDUFA on April 28. And Seigerman pointed out that Bristol-Myers shares are undervalued given the company’s strong fundamentals.

Plus Seigerman believes that the company’s margin leverage is underestimated. 

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Link to Source

Recent Publications of Bristol-Myers Squibb Company

Leave a Comment

SOTD Membership

Register by Email

or
Already a member? Sign In